VERU Veru Inc
Price (delayed)
$0.6348
Market cap
$92.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$69.84M
Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111,
Highlights
The quick ratio has soared by 100% from the previous quarter and by 62% YoY
The EPS has soared by 64% YoY and by 7% from the previous quarter
Veru's revenue has decreased by 13% QoQ but it has increased by 7% YoY
The equity has contracted by 48% YoY and by 18% from the previous quarter
The gross margin has contracted by 36% YoY and by 8% from the previous quarter
Key stats
What are the main financial stats of VERU
Market
Valuations
Earnings
Shares outstanding
146.38M
Market cap
$92.92M
Enterprise value
$69.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.49
Price to sales (P/S)
6.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.74
Revenue
$14.75M
Gross profit
$4.7M
Operating income
-$39.28M
Net income
-$38.47M
EBIT
-$37.23M
EBITDA
-$36.97M
Free cash flow
-$27.15M
Per share
Balance sheet
Liquidity
EPS
-$0.26
EPS diluted
-$0.26
Free cash flow per share
-$0.19
Book value per share
$0.18
Revenue per share
$0.1
TBVPS
$0.23
Total assets
$39.83M
Total liabilities
$13.2M
Debt
$3.52M
Equity
$26.63M
Working capital
$22.03M
Debt to equity
0.13
Current ratio
4.47
Quick ratio
4.19
Net debt/EBITDA
0.62
Margins
Efficiency
Dividend
EBITDA margin
-250.7%
Gross margin
31.9%
Net margin
-260.9%
Operating margin
-266.4%
Return on assets
-65%
Return on equity
-108.5%
Return on invested capital
-210%
Return on capital employed
-111.2%
Return on sales
-252.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERU stock price
How has the Veru stock price performed over time
Intraday
-0.78%
1 week
19.91%
1 month
22.15%
1 year
-18.01%
YTD
-2.41%
QTD
29.52%
Financial performance
How have Veru's revenue and profit performed over time
Revenue
$14.75M
Gross profit
$4.7M
Operating income
-$39.28M
Net income
-$38.47M
Gross margin
31.9%
Net margin
-260.9%
VERU's net margin is up by 43% year-on-year but it is down by 17% since the previous quarter
The net income has grown by 39% YoY
The company's operating margin rose by 39% YoY but it fell by 22% QoQ
The gross margin has contracted by 36% YoY and by 8% from the previous quarter
Growth
What is Veru's growth rate over time
Valuation
What is Veru stock price valuation
P/E
N/A
P/B
3.49
P/S
6.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.74
The EPS has soared by 64% YoY and by 7% from the previous quarter
The equity has contracted by 48% YoY and by 18% from the previous quarter
The P/B is 32% below the 5-year quarterly average of 5.2 but 21% above the last 4 quarters average of 2.9
VERU's price to sales (P/S) is 35% less than its 5-year quarterly average of 9.7 and 21% less than its last 4 quarters average of 8.0
Veru's revenue has decreased by 13% QoQ but it has increased by 7% YoY
Efficiency
How efficient is Veru business performance
Veru's ROE has soared by 53% YoY but it has decreased by 20% from the previous quarter
The return on invested capital has grown by 45% year-on-year but it has declined by 27% since the previous quarter
The ROS has grown by 43% YoY but it has contracted by 17% from the previous quarter
The ROA has grown by 32% YoY but it has contracted by 19% from the previous quarter
Dividends
What is VERU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERU.
Financial health
How did Veru financials performed over time
The quick ratio has soared by 100% from the previous quarter and by 62% YoY
The company's total liabilities has shrunk by 54% YoY and by 53% QoQ
VERU's debt is 87% smaller than its equity
The equity has contracted by 48% YoY and by 18% from the previous quarter
The debt to equity is up by 44% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.